Table 4. Outcome data.
| Outcome measure | Control weeks prior to 4-AP Mean (SD) | 4-AP Mean (SD) | Control weeks prior to t-butyl Mean (SD) | t-butyl Mean (SD) | ß k 0 | P value | ß k 1 | P value | Ave. Imp. |
| OFS | 3.63 (2.10) | 4.73 (1.42) | 3.78 (1.57) | 4.45 (1.45) | 0.62 | 0.005 | 0.15 | 0.31 | 0.66 |
| SS + support | 17.39 (13.57) | 37.24 (20.94) | 16.85 (11.65) | 29.18 (20.28) | 13.6 | <0.0001 | 1.9 | 0.51 | 13.4 |
| SS -support* | 2.51 (4.89) | 5.71 (13.72) | 0.98 (1.70) | 5.32 (13.93) | |||||
| RI + support | 4.95 (3.79) | 13.1 (11.95) | 3.98 (3.67) | 6.97 (8.83) | 4.7 | 0.028 | 2.2 | 0.13 | 4.9 |
| RI -support* | 0.79 (1.54) | 1.84 (4.99) | 0.36 (0.63) | 1.45 (4.07) | |||||
| HL DNI + support | NA | D:0 N:7 I:10 | NA | D:0 N:6 I:9 | 0.17 | 0.035 | 0.17 | 0.13 | 0.66 |
| HL DNI no support* | NA | D:0 N:11 I:6 | NA | D:0 N:10 I:5 | 0.25 | 0.076 | 0.061 | 0.54 | 0.27 |
| Tail wag DNI | NA | D:0 N:13 I:4 | NA | D:0 N:12 I:3 | 0.055 | 0.29 | 0.002 | 0.94 | 0.0625 |
| Urination DNI | NA | D:0 N:15 I:2 | NA | D:0 N:15 I:0 | 0.059 | 0.18 | 0.059 | 0.18 | 0.063 |
Control weeks: 2 weeks period immediately preceding treatment with either 4-AP or t-butyl; OFS: open field score (0–13); SS: stepping score; RI: regularity index; DNI: decreased (−1), no change (0), improved (+1); HL: hind limb; ß k 0: treatment effect of 4-AP or t-butyl relative to control; ß k 1: relative treatment effects of 4-AP and t-butyl. Positive values of ß k 1 reflect outperformance by 4-AP, and negative values reflect t-butyl. The scores denoted with * were not changed by treatment, therefore ß k 0 and ß k 1 values could not be calculated.